Others titles

  • Clinical Trial on Stroke
  • RCT on Stroke

Keywords

  • Stroke
  • Clinical trials
  • RCTs
  • Randomized Controlled Trials
  • Acute Stroke
  • Ischaemic Stroke
  • Haemorrhagic Stroke
  • Pulmonary embolism
  • Coronary heart disease
  • Pneumonia

International Stroke Trial Database

The International Stroke Trial (IST) dataset includes data on 19,435 patients and 112 variables. For each randomized patient, data were extracted on the variables assessed at randomization, at the early outcome point, and at 6-months. This dataset provides a source of primary data and is available for public use for the conduct of secondary analyses and in the planning of future trials particularly in older patients and in resource-poor settings given the age distribution of the dataset.

Log in to download
Complexity

Get The Data

For getting access to data download links please read and accept the end-user license agreement.
Your Data License
  • Research
    Non-Commercial, Share-Alike, Attribution Free Forever
  • Commercial
    Commercial Use, Remix & Adapt, White Label Log in to download

John Snow Labs Standard End User License Agreement

Last updated:January 20, 2021

This Standard End User License Agreement (“EULA”) applies to customers of John Snow Labs Inc. (as defined below), using any product of John Snow Labs Inc. on John Snow Labs Marketplace as defined below (hereinafter referred to “you”) and John Snow Labs Inc., a Delaware corporation (“John Snow Labs”, “we” or “us”).

By downloading, installing, and/or using (as applicable) any Product of John Snow Labs (as defined below), you automatically agree to be bound by, and use our Products in compliance with, this EULA. This EULA, together with additional terms and conditions and/or policies referenced herein or located on https://www.johnsnowlabs.com and/or conveyed to you by John Snow Labs, is a legally binding contract between you and John Snow Labs.

PLEASE READ THIS EULA CAREFULLY BEFORE PURCHASING, INSTALLING OR USING OUR PRODUCTS MADE AVAILABLE ON JOHN SNOW LABS MARKETPLACE.

We may make changes to this EULA from time to time. When we do so, we will revise the “last updated” date given above. The then-current version of this EULA will supersede all earlier versions. You agree that your continued use of our Products after such changes have been published to our EULA will constitute your acceptance of such revised EULA.

Definitions

“John Snow Labs Data Library” means a data library located at https://www.johnsnowlabs.com;

“Products” means products and services of John Snow Labs that you download and use from listings in John Snow Labs Data Library;

Important Notice

By installing and using our Products, you acknowledge that the use of the Products can be subject to the restrictions and controls imposed by United States export regulations.

You represent and warrant that you do not intend to use the Products for any purpose prohibited by United States export regulations, including, without limitation, terrorism, cyber-attacks, cyber-crimes, money-laundering, industrial espionage, or nuclear, chemical or biological weapons proliferation. Further, you represent and warrant that you are not listed as a denied party on any list governing United States exports.

Eligibility

Our Products can be used by an individual, business or other legal entity, or both. If you are entering into this EULA, or using the Products, on behalf of a company or other legal entity, you represent that you have the authority to bind such entity to this EULA, in which case “you” shall refer to such entity.

In the event you have entered into a separate written agreement with John Snow Labs regarding the Products that contemplates terms that are inconsistent with this EULA, the written agreement shall control and this EULA will not apply to you to the extent inconsistent with such written agreement, or, if such written agreement is contemplated to be in lieu of this EULA, then this EULA shall not apply at all.

Your Access and Use

Subject to your compliance with this EULA, as well as any other applicable policies, John Snow Labs grants you non-exclusive, non-transferable, license to install, access to, modify, and use of, the Products worldwide (subject to applicable export laws) during the term of this EULA (as described below) solely for research, private study and personal use of Products.

This license is personal to you, and you may not resell our Products, permit other users access to our Products through your account. Your right to use our Products is limited by all terms and conditions set forth in this EULA.

Except for your pre-existing rights and this license granted to you, we and our licensors retain all rights, titles and interests in and to our Products, all related intellectual property rights, including trademarks (whether registered or pending), domain and business names. Our Products are protected by applicable intellectual property laws, including United States copyright law and international treaties.

Except for the foregoing license, you have no other rights in the Products and you may not modify, edit, copy, reproduce, create derivative works of, reverse engineer, alter, enhance or in any way exploit the Products in any manner. If you breach any of this EULA, the above license will terminate automatically.

You will be deemed to have taken any action that you permit, assist or facilitate any person or entity to take related to this EULA, your content or use of the Products. You are responsible for end users’ use of your content and the Products. You will ensure that all end users comply with your obligations under this EULA and that the terms of your agreement with each end user are consistent with this EULA. If you become aware of any violation of your obligations under this EULA caused by an end user, you will immediately suspend access to your content and the Products by such end user. We do not provide any support or services to end users unless we have a separate agreement with you or an end user obligating us to provide such support or services.

Restrictions

You will access or use our Products solely via John Snow Labs Data Library.

Except as otherwise explicitly provided in this EULA or as may be expressly permitted by applicable law, you will not, and will not permit or authorize any third party to:

  1. reproduce, modify, translate, enhance, decompile, disassemble, reverse engineer or create derivative works of any of our Products or its technological features or measures;
  2. rent, lease, sell, resell, loan, distribute, or sublicense access to any of our Products;
  3. circumvent or disable any security or technological features or measures of our Products;
  4. use our intellectual property rights without our express prior written authorization;
  5. use our Products for more than one trial period, unless the trial period is extended by John Snow Labs’ prior written permit;
  6. use our Products with an intent to build a competitive product or service, or copy or substantially copy any ideas, features, functions, organization, structure, application program interface, graphics, or user interface of the Products;
  7. store, copy, modify, distribute, or resell any of the information; audio, visual, and audiovisual works, or other content made available on our Products (collectively, “Content”) or compile or collect any Content as part of a database or other work;
  8. use any automated tool (e.g., robots, spiders) to access or use our Products, or to store, copy, modify, distribute, or resell any Content;
  9. circumvent or disable any rights management, usage rules, or other security features of our Products;
  10. use our Products in a manner that overburdens, or that threatens the integrity, performance, or availability of, our Products; or
  11. remove, alter, or obscure any proprietary notices (including copyright and trademark notices) on any portion of our Products or any Content.

Fees and Taxes

Your use of the Products is subject to our fees. All fees are given on our website https://www.johnsnowlabs.com. Except as set forth in this EULA, the fees are non-refundable. We are entitled to revise our fees from time to time.

The fees exclude any federal, state or local taxes, VAT, GST, or similar taxes. You are responsible for identification and payment of all taxes as required by applicable law.

Term and Termination

This EULA will become effective as of the date of your order of Products and shall be in effect until terminated.

John Snow Labs may suspend or terminate your right to use our Products, if you or your end user’s use of the Products:

  1. is in breach of this EULA;
  2. poses a security risk to our Products;
  3. could adversely impact our systems, the Products or other customers;
  4. could subject us, our affiliates, or any third party to liability; or
  5. could be fraudulent.

We may also suspend or terminate your right to use our Products, if you fail to perform your payment obligations, or you have ceased to operate in the ordinary course, made an assignment for the benefit of creditors or similar disposition of your assets, or become the subject of any bankruptcy, reorganization, liquidation, dissolution or similar proceeding.

We may also suspend or terminate your right to use our Products without any reason upon a relevant 30 days’ written notice to you and will refund the unused fees pre-paid by you for access to the Products for the affected time period (if any). Where your access is suspended or terminated by the breach of this EULA or applicable laws, John Snow Labs will will not provide, or be liable for, any refund.

You will cease use of the Products during any period of suspension, or upon termination of this EULA.

All provisions which by their nature are intended to survive termination shall survive termination of this EULA.

Support

If applicable to your Product, John Snow Labs will provide you with the support services. If you use a trial access, support services are excluded. Under this EULA, our support services exclude any installation, training, maintenance services (including any error corrections, bug fixes, or new releases), technical assistance, consulting services, or other services of any kind. Such services are provided at John Snow Labs’ discretion.

From time to time John Snow Labs can perform updates to our software. If available, such updates may include bug fixes, new features and/or enhancements. You are solely responsible for deploying such updates at your own risk and liability.

Access to our Products

We do not provide you with the equipment to access our Products. You are responsible for all fees charged by third parties related to your access and use of our Products (e.g., charges by Internet service providers).

You are responsible for monitoring your use of the Products, including payment of all fees and/or taxes related to such access and use. You agree that John Snow Labs is permitted to request and you hereby consent to provide John Snow Labs information related to your use of the Products for auditing purposes.

You also certify that you are legally permitted to use the Products, and take full responsibility for the selection and use of the Products. This EULA is void where prohibited by law, and the right to use the Products is revoked in such jurisdictions. John Snow Labs makes no claim that the Products may be lawfully used outside of the United States. If you use the Products from outside of the United States, you do so at your own risk and you are responsible for compliance with the laws of jurisdiction.

Privacy Policy

We may collect, store and receive personal and other information about you through our Products. Our collection and use of this information is governed by our Privacy Policy available at https://www.JohnSnowLabs.com/privacy/ which may be amended from time to time.

Links and Third Party Content

Our Products may display, or contain links to, third party products, services, and websites. Any opinions, advice, statements, services, offers, or other information that constitutes part of the content expressed, authored, or made available by other users or other third parties, or which is accessible through or may be located using our Products (collectively, “Third Party Content”) are those of the respective authors or producers and not of us or our shareholders, directors, officers, employees, agents, or representatives.

We do not control Third Party Content and do not guarantee the accuracy, integrity or quality of such Third Party Content. We are not responsible for the performance of, we do not endorse, and we are not responsible or liable for, any Third Party Content or any information or materials advertised in any Third Party Content. By using our Products, you may be exposed to content that is offensive, indecent, or objectionable. We are not responsible or liable, directly or indirectly, for any damage or loss caused to you by your use of or reliance on any goods, services, or information available on or through any third party service or Third Party Content. It is your responsibility to evaluate the information, opinion, advice, or other content available on and through our Products.

Proprietary Rights

John Snow Labs will not obtain any rights under this EULA from you (or your licensors) to your content.

The Products, including software, is and remains the exclusive property of John Snow Labs and its licensors. Except for the access and use rights expressly set forth in this EULA, no license or other rights in or to the Products or John Snow Labs trademark(s) and other intellectual property rights therein, are granted to you, and all such licenses and rights are expressly reserved. You will not remove, alter, or obscure any proprietary notices (including copyright and trademark notices) on any portion of our Products or any Content.

Trademarks

“John Snow Labs,” the John Snow Labs logo, and any other product, business or service name or slogan, whether registered or pending, displayed on our Products are trademarks of John Snow Labs, Inc. or its suppliers or licensors, and may not be copied, imitated or used, in whole or in part, without the prior written permission of John Snow Labs or the applicable trademark holder. You may not use any metatags or any other “hidden text” utilizing “John Snow Labs” or any other name, trademark or product, business or service name of John Snow Labs without our prior written permission. In addition, the look and feel of our Products, including all page headers, custom graphics, button icons and scripts, is the service mark, trademark and/or trade dress of John Snow Labs and may not be copied, imitated or used, in whole or in part, without our prior written permission. All other trademarks, pending trademarks, registered trademarks, product names and company names or logos mentioned in our Products are the property of John Snow Labs Inc. and/or their respective owners. Reference to any products, services, processes or other information, by trade name, trademark, manufacturer, supplier, or otherwise does not constitute or imply endorsement, sponsorship, or recommendation thereof by us.

Disclaimer of Warranties

YOUR USE OF THE PRODUCTS IS AT YOUR SOLE RISK. THE PRODUCTS AND CONTENT EACH ARE PROVIDED ON AN “AS IS” AND “AS AVAILABLE” BASIS. WE AND OUR SUPPLIERS AND LICENSORS EXPRESSLY DISCLAIM ALL WARRANTIES OF ANY KIND, WHETHER EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, AND NON-INFRINGEMENT. WE DO NOT GUARANTEE THE ACCURACY, COMPLETENESS, OR USEFULNESS OF THE PRODUCTS OR ANY CONTENT, AND YOU RELY ON THE PRODUCTS AND CONTENT AT YOUR OWN RISK. ANY MATERIAL THAT YOU ACCESS OR OBTAIN THROUGH OUR PRODUCTS IS DONE AT YOUR OWN DISCRETION AND RISK AND YOU WILL BE SOLELY RESPONSIBLE FOR ANY DAMAGE TO YOUR COMPUTER OR LOSS OF DATA THAT RESULTS FROM THE DOWNLOAD OF ANY MATERIAL THROUGH OUR PRODUCTS. NO ADVICE OR INFORMATION, WHETHER ORAL OR WRITTEN, OBTAINED BY YOU FROM US OR THROUGH OR FROM OUR PRODUCTS WILL CREATE ANY WARRANTY NOT EXPRESSLY STATED IN THIS EULA. SOME STATES MAY PROHIBIT A DISCLAIMER OF WARRANTIES AND YOU MAY HAVE OTHER RIGHTS THAT VARY FROM STATE TO STATE.

Limitation of Liability

WE AND OUR SUPPLIERS AND LICENSORS WILL NOT BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL, OR EXEMPLARY DAMAGES, INCLUDING BUT NOT LIMITED TO, DAMAGES FOR LOSS OF PROFITS, GOODWILL, USE, DATA, OR OTHER INTANGIBLE LOSSES (EVEN IF WE HAVE BEEN ADVISED OF THE POSSIBILITY OF THESE DAMAGES), RESULTING FROM YOUR USE OF OUR PRODUCTS AND CONTENT. UNDER NO CIRCUMSTANCES WILL THE TOTAL LIABILITY OF US AND OUR SUPPLIERS AND LICENSORS OF ALL KINDS ARISING OUT OF OR RELATED TO YOUR USE OF THE PRODUCTS AND CONTENT (INCLUDING BUT NOT LIMITED TO WARRANTY CLAIMS), REGARDLESS OF THE FORUM AND REGARDLESS OF WHETHER ANY ACTION OR CLAIM IS BASED ON CONTRACT, TORT, OR OTHERWISE, EXCEED THE AMOUNTS, IF ANY, THAT YOU HAVE PAID FOR YOUR USE OF THE PRODUCTS AND CONTENT. BECAUSE SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF LIABILITY FOR CONSEQUENTIAL OR INCIDENTAL DAMAGES, THE ABOVE LIMITATION MAY NOT APPLY TO YOU.

Indemnity

To the full extent permitted by applicable law, you shall defend, indemnify and hold harmless John Snow Labs, its affiliates and its licensors, and each of their respective employees, officers, directors, and representatives from and against any claims, damages, losses, liabilities, costs, and expenses (including reasonable attorney’s fees) arising out of or relating to any third party claim concerning: (a) your use of the Products; (b) breach of this EULA or violation of applicable law by you; (c) any content or the combination of such content with other software, content or processes, including any claim involving alleged infringement or misappropriation of third-party rights by such content or combination; or (d) breach of any obligation or duty you owe to a third party.

Legal Notices

Enforcement of this EULA will be governed by the laws of the State of Delaware, excluding its conflict and choice of law principles. The exclusive jurisdiction and venue for any claims arising out of or related to this EULA or your use of the Products will lie in the state and federal courts located in Sussex County, within the State of Delaware, and you irrevocably agree to submit to the jurisdiction of such courts. Our failure to enforce any right or provision in this EULA will not constitute a waiver of such right or provision unless acknowledged and agreed by us in writing. In the event that a court of competent jurisdiction finds any provision of this EULA to be illegal, invalid, or unenforceable, the remaining provisions will remain in full force and effect.

Notifications

We may use your contact information to notify you if we have any legitimate interest or if we need to notify you on any important information related to your use of Products. We will not send you newsletters unless you expressly consented to such notifications.

Contacting Us

If you have any questions or concerns about our Products or this EULA, you may contact us by email at support@JohnSnowLabs.com.

Description

The International Stroke Trial (IST) is one of the largest randomized trials ever conducted on individual patients in acute stroke. The IST dataset includes data on 19 435 patients with acute stroke, with 99% complete follow-up. Over 26.4% patients were aged over 80 years at study entry. Background stroke care was limited and none of the patients received thrombolytic therapy.

This clinical trial was conducted between 1991 and 1996 and a pilot phase between 1991 to and 1993. This study is a large, prospective, randomized controlled trial, with 100% complete baseline data and over 99% complete follow-up data. For each randomized patient, data were extracted on the variables assessed at randomization; the early outcome point was 14-days after randomization or prior discharge, and at 6-months and provided as an analyzable database. The aim of the trial was to establish whether early administration of aspirin, heparin, both or neither influenced the clinical course of an acute ischaemic stroke.

About this Dataset

Data Info

Date Created

2011-11-02

Last Modified

2011-11-02

Version

2

Update Frequency

Never

Temporal Coverage

1991 to 1996

Spatial Coverage

World

Source

John Snow Labs; Department of Biostatistics, Vanderbilt University; University of Edinburgh, Department of Clinical Neurosciences;

Source License URL

Source License Requirements

N/A

Source Citation

N/A

Keywords

Stroke, Clinical trials, RCTs, Randomized Controlled Trials, Acute Stroke, Ischaemic Stroke, Haemorrhagic Stroke, Pulmonary embolism, Coronary heart disease, Pneumonia

Other Titles

Clinical Trial on Stroke, RCT on Stroke

Data Fields

Name Description Type Constraints
Hospital_NumberHospital numberintegerlevel : Nominalrequired : 1
Delay_in_Hours_at_RandomizationDelay between stroke and randomization in hoursintegerlevel : Ratio
Conscious_State_at_RandomizationConscious state at randomization where F - fully alert, D - drowsy, U - unconsciousstring-
GenderSex where Value: Male, Femalestring-
Age_in_YearsAge in years of subjectsintegerlevel : Ratio
Is_Symptoms_Noted_on_WakingSymptoms noted on waking whereboolean-
Is_Atrial_Fibrillation_CodedAtrial fibrillation; not coded for pilot phase - 984 patientsboolean-
Is_CT_Before_RandomizationCT before randomizationboolean-
Is_Infarct_Visible_on_CTInfarct visible on CTboolean-
Is_Heparin_Before_RandomizationHeparin within 24 hours prior to randomizationboolean-
Is_Aspirin_Before_RandomizationAspirin within 3 days prior to randomizationboolean-
Systolic_Blood_Pressure_at_RandomizationSystolic blood pressure at randomisation (mmHg)integerlevel : Ratio
Face_DeficitPresence or absence of face deficit where Y = True, N = False, C=can't assessstring-
Arm_Hand_DeficitPresence or absence of an arm or hand deficit where Y = True, N = False, C=can't assessstring-
Leg_Foot_DeficitPresence or absence of leg or foot deficit where Y = True, N = False, C=can't assessstring-
DysphasiaPresence or absence of dysphasia where Y = True, N = False, C=can't assessstring-
HemianopiaPresence or absence of hemianopia where Y = True, N = False, C=can't assessstring-
Visuospatial_DisorderPresence or absence of visuospatial disorder where Y = True, N = False, C=can't assessstring-
Cerebellar_SignsPresence or absence of brainstem or cerebellar signs where Y = True, N = False, C=can't assessstring-
Deficit_OthersPresence or absence of other deficit where Y = True, N = False, C=can't assessstring-
Stroke_SubtypeA subtype of stroke, either total anterior circulation syndrome (TACS), partial anterior circulation syndrome (PACS), posterior circulation syndrome (POCS) and lacunar syndrome (LACS), and other (OTH)string-
Date_of_Randomization_OxfordYear and month of randomization done every March 1 from 1991 to 1996; the date is in Oxford format (yyyy-mm); date of randomization per country is coded by country and year (code-yy)string-
Local_Time_in_HoursLocal time in hours; (99-missing data) of randomization droppedintegerlevel : Ordinal
Local_Time_in_MinutesLocal time in minutes; (99-missing data) of randomisationintegerlevel : Ordinal
Local_Day_of_WeekEstimate of the local day of the week (assuming date is Oxford) where 1 - Sunday, 2-Monday, 3-Tuesday, 4-Wednesday, 5-Thursday, 6-Friday,string-
Is_Trial_Aspirin_AllocatedTrial aspirin allocatedboolean-
Trial_Heparin_AllocatedTrial heparin allocated (M/L/N) where M in the main trial is coded as H=high in pilot; where M = high in the main trial, H = high in pilot, L = low in the main trial and N = avoid heparin; The terminology for the allocated dose of unfractioned heparin changed slightly from the pilot to the main study. Patients were allocated either 12500 units subcutaneously twice daily (coded as H in the pilot and M in the main trial), 5000 units twice daily (coded as L throughout) or to 'avoid heparin' (coded as N throughout).string-
Aspirin_Given_For_14_DaysAspirin given for 14 days or till death or discharge where Y = True, N = False, U = Unknownstring-
Discharged_On_Long_Term_AspirinDischarged on long term aspirin (Y/N) where Y = True, N = False, U = Unknownstring-
Low_Dose_Heparin_Given_For_14_DaysLow dose heparin given for 14 days or till death/discharge where Y = True, N = False, U = Unknownstring-
Medium_Dose_Heparin_Given_For_14_DaysMedium dose heparin given for 14 days or till death/discharge where Y = True, N = False, U = Unknownstring-
Is_Medium_Dose_Heparin_Given_For_14_Days_in_PilotMedium dose heparin is given for 14 days etc in the pilot (combine with above)boolean-
Time_In_Days_On_Trial_TreatmentEstimate of time in days on trial treatmentintegerlevel : Ordinal
Non_Trial_Subcutaneous_HeparinNon trial subcutaneous heparin (Y/N) where Y = True, N = False, U = Unknownstring-
Non_Trial_Intravenous_HeparinNon trial intravenous heparin where Y = True, N = False, U = Unknownstring-
Non_Trial_Antiplatelet_DrugNon trial antiplatelet drug where Y = True, N = False, U = Unknownstring-
Anticoagulants_OthersOther anticoagulants given where Y = True, N = False, U = Unknownstring-
Glycerol_or_ManitolGlycerol or manitol given where Y = True, N = False, U = Unknownstring-
SteroidsSteroids given where Y = True, N = False, U = Unknownstring-
Calcium_AntagonistsCalcium antagonists given where Y = True, N = False, U = Unknownstring-
HaemodilutionOccurence of haemodilution where Y = True, N = False, U = Unknownstring-
Carotid_SurgeryOccurence of carotid surgery where Y = True, N = False, U = Unknownstring-
ThrombolysisOccurence of thrombolysis where Y = True, N = False, U = Unknownstring-
Major_Non_Cerebral_HaemorrhageOccurence of major non-cerebral haemorrhage where Y = True, N = False, U = Unknownstring-
Days_Elapsed_From_Randomization_to_Major_Non_Cerebral_HaemorrhageNumber of days elapsed from randomization to occurrence of major non-cerebral hemorrhageintegerlevel : Ratio
Comment_on_Major_Non_Cerebral_HaemorrhageComment on the occurrence of major non-cerebral hemorrhagestring-
Side_Effect_OthersOccurrence of other side effect where Y = True, N = False, U = Unknownstring-
Days_Elapsed_From_Randomization_to_Side_EffectsNumber of days elapsed from randomization to occurrence of other side effectsintegerlevel : Ratio
Comment_on_Side_EffectComment on the occurrence of other side effectsstring-
Ischaemic_StrokeIschaemic stroke as final diagnosis of initial event where Y = True, N = False, U = Unknownstring-
Haemorrhagic_StrokeHemorrhagic stroke as a final diagnosis of initial event where Y = True, N = False, U = Unknownstring-
Indeterminate_StrokeIndeterminate stroke as final diagnosis of initial event where Y = True, N = False, U = Unknownstring-
Not_A_StrokeNot a stroke as final diagnosis of initial event where Y = True, N = False, U = Unknownstring-
Comment_on_Final_Diagnosis_of_Initial_EventComment on final diagnosis of the initial eventstring-
Recurrent_Ischaemic_StrokeOccurrence of ischaemic recurrent stroke within 14 days where Y = True, N = False, U = Unknownstring-
Days_Elapsed_From_Randomization_to_Recurrent_Ischaemic_StrokeNumber of days elapsed from randomization to occurrence of recurrent ischaemic strokeintegerlevel : Ratio
Recurrent_Haemorrhagic_StrokeOccurrence of haemorrhagic stroke within 14 days where Y = True, N = False, U = Unknownstring-
Days_Elapsed_From_Randomization_to_Recurrent_Haemorrhagic_StrokeNumber of days elapsed from randomization to occurrence of hemorrhagic strokeintegerlevel : Ratio
Unknown_TypeOccurrence of unknown type stroke within 14 days where Y = True, N = False, U = Unknownstring-
Days_Elapsed_From_Randomization_to_Unknown_TypeNumber of days elapsed from randomization to occurrence of an unknown type of strokeintegerlevel : Ratio
Pulmonary_Embolism_Within_14_DaysOccurrence of pulmonary embolism within 14 days where Y = True, N = False, U = Unknownstring-
Days_Elapsed_From_Randomization_to_Pulmonary_EmbolismNumber of days elapsed from randomization to occurrence of pulmonary embolism within 14 daysintegerlevel : Ratio
Discharged_Alive_From_Hospital_Within_14_DaysDischarged alive from hospital within 14 days where Y = True, N = False, U = Unknownstring-
Days_Elapsed_From_Randomization_to_Discharged_Alive_From_HospitalNumber of days elapsed from randomization to discharge alive from the hospital within 14 daysintegerlevel : Ratio
Discharge_DestinationDischarge destination where A = Home, B = Relatives home, C = Residential care, D = Nursing home, E = Other hospital departments and U-Unknownstring-
Dead_on_Discharge_Within_14_DaysThe occurrence of death upon discharge where Y = True, N = False, U = Unknown; This death is not necessarily within 14 days of randomizationstring-
Days_Elapsed_From_Randomization_to_Dead_on_DischargeNumber of days elapsed from randomization to dead on discharge where death is not necessarily within 14 days of randomizationintegerlevel : Ratio
Cause_of_Death_Within_14_DaysCause of death where 1 = Initial stroke, 2 = Recurrent stroke (ischaemic or unknown), 3 = Recurrent stroke (haemorrhagic, 4= Pneumonia, 5 = Coronary heart disease, 6 = Pulmonary embolism, 7 = Other vascular or unknown, 8 = Non-vascular and 0 = unknownstring-
Comment_on_Death_Within_14_DaysComment on death within 14 daysstring-
Dead_at_Six_Month_Follow_UpOccurrence of death at six month follow-up where Y = True, N = False, U = Unknownstring-
Days_Elapsed_From_Randomization_to_Date_of_Last_ContactNumber of days elapsed from randomization to date of the last contactintegerlevel : Ratio
Days_Elapsed_From_Randomization_to_Death_at_Six_Month_Follow_UpNumber of days elapsed from randomization to death at six-month follow-up where death is not necessarily within 6 months of randomizationintegerlevel : Ratio
Cause_of_Death_at_Six_Month_Follow_UpCause of death where 1 = Initial stroke, 2 = Recurrent stroke (ischaemic or unknown), 3 = Recurrent stroke (haemorrhagic, 4= Pneumonia, 5 = Coronary heart disease, 6 = Pulmonary embolism, 7 = Other vascular or unknown, 8 = Non-vascular and 0 = unknownstring-
Comment_on_Death_at_Six_Month_Follow_UpComment on death at six-month follow-upstring-
Fully_Recovered_at_Six_Month_Follow_UpFully recovered at six month follow-up where Y = True, N = False, U = Unknownstring-
Dependent_at_Six_Month_Follow_UpDependent at six month follow-up where Y = True, N = False, U = Unknownstring-
Place_of_Residence_at_Six_Month_Follow_UpPlace of residence at six month follow-up where A = Home, B = Relatives home, C = Residential care, D = Nursing home, E = Other hospital departments and U = Unknownstring-
On_Antiplatelet_Drugs_at_Six_Month_Follow_UpOn antiplatelet drugs at six month follow-up where Y = True, N = False, U = Unknownstring-
On_Anticoagulants_at_Six_Month_Follow_UpOn anticoagulant at six month follow-up where Y = True, N = False, U = Unknownstring-
Days_Elapsed_From_Randomization_to_Date_Discharge_Form_ReceivedNumber of days elapsed from randomization to date discharged form receivedintegerlevel : Ratio
Days_Elapsed_From_Randomization_to_Date_at_Six_Month_Follow_Up_DoneNumber of days elapsed from randomization to date at six-month follow-upintegerlevel : Ratio
Abbreviated_Country_CodeAbbreviated country codestring-
Country_CodeCountry codeintegerlevel : Nominal
Days_Elapsed_From_Randomization_to_Date_Discharge_Form_CompletedNumber of days elapsed from randomization to date discharge form completedintegerlevel : Ratio
Coding_of_ComplianceCoding of compliance where provisional categories for non-compliance are the following:string-
Is_Compliant_for_AspirinCompliance with aspirinboolean-
Is_Compliant_for_HeparinCompliance with heparinboolean-
Is_Death_IndicatorIndicator for deathboolean-
Time_of_Death_in_DaysTime of death or censoring in daysintegerlevel : Ordinal
Predicted_Probability_of_DeathPredicted probability of death or dependence at 6 monthnumberlevel : Ratio
Predicted_Probability_of_Death_at_Six_MonthPredicted probability of death at 6 monthnumberlevel : Ratio
Predicted_Probability_of_Death_at_14_DaysPredicted probability of death at 14 daysnumberlevel : Ratio
Is_Dead_or_Alive_at_14_DaysKnown to be dead or alive at 14 days where 1 = yes and 0 = no; this does not necessarily mean that we know the outcome at 6 monthsboolean-
Is_Death_Indicator_at_14_DaysThe indicator of death at 14 daysboolean-
Six_Month_OutcomeSix month outcome where 1 = dead, 2 = dependent, 3 = not recovered, 4 = recovered, 0 or 9 = missing statusstring-
Is_Initial_Stroke_IndicatorInitial stroke as an indicator variable for the specific cause of deathboolean-
Is_Recurrent_Ischaemic_or_Unknown_Stroke_IndicatorRecurrent ischaemic or unknown stroke as an indicator variable for the specific cause of deathboolean-
Is_Recurrent_Haemorrhagic_Stroke_IndicatorRecurrent hemorrhagic stroke as an indicator variable for the specific cause of deathboolean-
Is_Pneumonia_IndicatorPneumonia as an indicator variable for the specific cause of deathboolean-
Is_Coronary_Heart_Disease_IndicatorCoronary heart disease as an indicator variable for the specific cause of deathboolean-
Is_Pulmonary_Embolism_IndicatorPulmonary embolism as an indicator variable for the specific cause of deathboolean-
Is_Other_Vascular_IndicatorOther vascular or unknown as an indicator variable for the specific cause of deathboolean-
Is_Non_Vascular_IndicatorNon-vascular as an indicator variable for the specific cause of deathboolean-
Is_Haemorrhagic_Stroke_Indicator_Within_14_DaysCerebral bleed/hemorrhagic stroke within 14 days as an indicator variable for the specific cause of death; this is slightly wider definition than DRSH and is used for analysis of cerebral bleedsboolean-
Is_Ischaemic_Stroke_Indicator_Within_14_DaysThe indicator of ischaemic stroke within 14 daysboolean-
Is_Indeterminate_Stroke_Indicator_Within_14_DaysThe indicator of indeterminate stroke within 14 daysboolean-
Is_Any_Stroke_Indicator_Within_14_DaysThe indicator of any stroke within 14 daysboolean-
Is_Haemorrhagic_Transformation_Indicator_Within_14_DaysThe indicator of hemorrhagic transformation within 14 daysboolean-
Is_Pulmonary_Embolism_Indicator_Within_14_DaysThe indicator of pulmonary embolism within 14 daysboolean-
Is_Deep_Vein_Thrombosis_on_DischargeThe indicator of deep vein thrombosis on the discharge formboolean-
Is_Major_Non_Cerebral_Bleed_Indicator_Within_14_DaysThe indicator of major non-cerebral bleed within 14 daysboolean-
Is_Any_Non_Cerebral_Bleed_Indicator_Within_14_DaysThe indicator of any non-cerebral bleed within 14 daysboolean-

Data Preview

Hospital NumberDelay in Hours at RandomizationConscious State at RandomizationGenderAge in YearsIs Symptoms Noted on WakingIs Atrial Fibrillation CodedIs CT Before RandomizationIs Infarct Visible on CTIs Heparin Before RandomizationIs Aspirin Before RandomizationSystolic Blood Pressure at RandomizationFace DeficitArm Hand DeficitLeg Foot DeficitDysphasiaHemianopiaVisuospatial DisorderCerebellar SignsDeficit OthersStroke SubtypeDate of Randomization OxfordLocal Time in HoursLocal Time in MinutesLocal Day of WeekIs Trial Aspirin AllocatedTrial Heparin AllocatedAspirin Given For 14 DaysDischarged On Long Term AspirinLow Dose Heparin Given For 14 DaysMedium Dose Heparin Given For 14 DaysIs Medium Dose Heparin Given For 14 Days in PilotTime In Days On Trial TreatmentNon Trial Subcutaneous HeparinNon Trial Intravenous HeparinNon Trial Antiplatelet DrugAnticoagulants OthersGlycerol or ManitolSteroidsCalcium AntagonistsHaemodilutionCarotid SurgeryThrombolysisMajor Non Cerebral HaemorrhageDays Elapsed From Randomization to Major Non Cerebral HaemorrhageComment on Major Non Cerebral HaemorrhageSide Effect OthersDays Elapsed From Randomization to Side EffectsComment on Side EffectIschaemic StrokeHaemorrhagic StrokeIndeterminate StrokeNot A StrokeComment on Final Diagnosis of Initial EventRecurrent Ischaemic StrokeDays Elapsed From Randomization to Recurrent Ischaemic StrokeRecurrent Haemorrhagic StrokeDays Elapsed From Randomization to Recurrent Haemorrhagic StrokeUnknown TypeDays Elapsed From Randomization to Unknown TypePulmonary Embolism Within 14 DaysDays Elapsed From Randomization to Pulmonary EmbolismDischarged Alive From Hospital Within 14 DaysDays Elapsed From Randomization to Discharged Alive From HospitalDischarge DestinationDead on Discharge Within 14 DaysDays Elapsed From Randomization to Dead on DischargeCause of Death Within 14 DaysComment on Death Within 14 DaysDead at Six Month Follow UpDays Elapsed From Randomization to Date of Last ContactDays Elapsed From Randomization to Death at Six Month Follow UpCause of Death at Six Month Follow UpComment on Death at Six Month Follow UpFully Recovered at Six Month Follow UpDependent at Six Month Follow UpPlace of Residence at Six Month Follow UpOn Antiplatelet Drugs at Six Month Follow UpOn Anticoagulants at Six Month Follow UpDays Elapsed From Randomization to Date Discharge Form ReceivedDays Elapsed From Randomization to Date at Six Month Follow Up DoneAbbreviated Country CodeCountry CodeDays Elapsed From Randomization to Date Discharge Form CompletedCoding of ComplianceIs Compliant for AspirinIs Compliant for HeparinIs Death IndicatorTime of Death in DaysPredicted Probability of DeathPredicted Probability of Death at Six MonthPredicted Probability of Death at 14 DaysIs Dead or Alive at 14 DaysIs Death Indicator at 14 DaysSix Month OutcomeIs Initial Stroke IndicatorIs Recurrent Ischaemic or Unknown Stroke IndicatorIs Recurrent Haemorrhagic Stroke IndicatorIs Pneumonia IndicatorIs Coronary Heart Disease IndicatorIs Pulmonary Embolism IndicatorIs Other Vascular IndicatorIs Non Vascular IndicatorIs Haemorrhagic Stroke Indicator Within 14 DaysIs Ischaemic Stroke Indicator Within 14 DaysIs Indeterminate Stroke Indicator Within 14 DaysIs Any Stroke Indicator Within 14 DaysIs Haemorrhagic Transformation Indicator Within 14 DaysIs Pulmonary Embolism Indicator Within 14 DaysIs Deep Vein Thrombosis on DischargeIs Major Non Cerebral Bleed Indicator Within 14 DaysIs Any Non Cerebral Bleed Indicator Within 14 Days
117DrowsyMale69TrueTrueTrue140nononoyesnoyesnoyespartial anterior circulation syndromesty-91WednesdayTrueavoid heparinyesyesnoFalse14nonononononononoyesnonononononononounknownnonoyesother hospital departments14187UK2713.0TrueTrueFalse1870.6980.23440.1054TrueFalsedependentFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalse
110Fully AlertMale76TrueTrueFalse150yesyesyesnononononolacunar syndromesty-91SaturdayFalselow in main trialnoyesyesFalse14nonononoyesnononoyesnonononononononounknownnonoyeshome16192UK27TrueTrueFalse1920.53890.15550.0421TrueFalsedependentFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalse
143Fully AlertFemale71FalseTrueFalse170yesyesyesnononononolacunar syndromesty-91TuesdayTrueavoid heparinyesyesnoFalse11nonononononononoyesnonononononoyes11.0nounknownnonoyeshome11189UK27TrueTrueFalse1890.52750.10090.0323TrueFalsedependentFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalse
16Fully AlertMale81FalseFalseFalse170nononoyesnonononopartial anterior circulation syndromesty-91SaturdayFalsehigh in pilotnoyesnoTrue14nonononoyesnononoyesnonononononoyes16.0nounknownnoyesnohome23183UK27TrueTrueFalse1830.40210.11470.0244TrueFalserecoveredFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalse
420Fully AlertMale78FalseFalseFalse170yesyesyesnononononolacunar syndromelut-91FridayTruehigh in pilotyesyesnoTrue14nonononononononoyesnonononononononounknownnonoyesother hospital departments17214UK27TrueTrueFalse2140.560.17090.0441TrueFalsedependentFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalse
139Fully AlertMale54FalseTrueFalse135yesyesyesnononononolacunar syndromelut-91MondayFalseavoid heparinnoyesnoFalse7nonononononononoyesnonononononoyes7.0nounknownnononohome16185UK27TrueTrueFalse1850.31320.04710.0244TrueFalsenot recoveredFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalse
14Fully AlertFemale77FalseFalseFalse140yesyesyesnononoyesnoposterior circulation syndromelut-91SundayTrueavoid heparinyesyesnoFalse14nononononononoyes14.0NOSE BLEED 15 MINSnononoyesnononononounknownnononohome15194UK2715.0TrueTrueFalse1940.72850.18730.053TrueFalsenot recoveredFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseTrue
124Fully AlertMale23FalseTrueFalse120nononononononoyesotherlut-91MondayFalselow in main trialnonoyesFalse11nonononononononoyesnonononononoyes11.0nounknownnononohome37193UK27TrueTrueFalse1930.150.00380.0054TrueFalsenot recoveredFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalse
118Fully AlertMale47FalseFalseFalse150nononononononoyesotherlut-91MondayTruehigh in pilotyesyesnoTrue5nonononononononoyesnonononononoyes5.0nounknownnononohome23193UK27TrueTrueFalse1930.13340.01620.0102TrueFalsenot recoveredFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalse
113Fully AlertMale81TrueFalseFalse170nononononoyesnoyespartial anterior circulation syndromelut-91MondayFalseavoid heparinnononoFalse14nonononononononoyesnonononononoyes14.0nounknownnonoyeshome42189UK27TrueTrueFalse1890.49640.14760.0337TrueFalsedependentFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalseFalse